Top 10 Products
Our ten top-selling products in 2009
The future of medicine lies in individual approaches and in building bridges between prevention, diagnosis and therapy. Bayer Schering Pharma meets this challenge with proven, successful products based on many decades of knowledge and experience.
| Product | Indication | Business Unit | Sales |
|---|---|---|---|
| YAZ®/ Yasmin®/ Yasminelle® |
hormonal contraceptive | Women's Healthcare | € 1,278 million |
| Betaferon®/Betaseron® | multiple sclerosis | Specialty Medicine | € 1,214 million |
| Kogenate® | hemophilia | Specialty Medicine | € 888 million |
| Adalat® | high blood pressure | General Medicine | € 633 million |
| Nexavar® | kidney and liver cancer | General Medicine | € 604 million |
| Mirena® | hormonal intrauterine delivery system for contraception | Women's Healthcare | € 490 million |
| Avalox®/Avelox® | respiratory tract infections | General Medicine | € 460 million |
| Levitra® | drug for treating erectile dysfunction | General Medicine | € 360 million |
| Cipro®/ Ciprobay® | infectious diseases (especially of the urinary passages) | General Medicine | € 331 million |
| Glucobay® | Diabetes | General Medicine | € 315 million |
Products are ranked by full year 2009 sales.
- Age-related macular degeneration (AMD)
- Breast cancer
- Contraception
- Diabetes
- Endometriosis
- Erectile Dysfunction (Erection Problems)
- Gynecological therapy
- Heartattack and stroke
- Hemophilia
- High blood pressure
- Infectious diseases
- Liver Cancer
- Menopausal Complaints
- Multiple sclerosis
- Non-Hodgkin's lymphomas
- Peripheral arterial occlusive disease
- Premenstrual Dysphoric Disorder (PMDD)
- Prostate cancer
- Pulmonary arterial hypertension
- Renalcell carcinoma
- Testosterone Deficiency
- Thromboses
© 2009 Bayer Schering Pharma Imprint
